Janssen Biotech, Inc.

Janssen Pharmaceutica Nv

Sherry La Porte

Jinquan Luo

Rajkumar Ganesan

Sanjaya Singh

Fang Yi

Raymond Brittingham

John Lee

Adam Zwolak

Sathyadevi Venkataramani

Colleen Kane

Theresa Marie McDevitt

Fei Shen

Degang Song

Triveni K Bhatt

Scott R Brodeur

Steven Jacobs

Marc Mercken

Chichi Huang

Wilson Edwards

Bianca Van Broeck

Michael Dennis Feldkamp

Yonghong Zhao

Jaclyn Hoover

The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3ε, polynucleotides encoding them, vectors, host cells, methods of making and using them.

Proteins comprising CD3 antigen binding domains and uses thereof

Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.

Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses

The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a human Kallikrein-2 (hK2), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereof

The invention provides antibodies or antigen binding fragments thereof that bind to 3pE A&#x3b2; and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other &#x3b2;-amyloid-related diseases.

Antibodies to pyroglutamate amyloid-&#x3b2; and uses thereof

Growing community of inventors

Horsham, PA, United States of America

Sherry La Porte